Imagion Biosystems Ltd has released a press release.
Imagion to complete the MagSense HER2 Phase 1 Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Imagion Biosystems Ltd. on 6ix
Earlier from Imagion Biosystems
- Imagion Announces New CEO
- Results of Non-renounceable Entitlement Offer
- Imagion Funding Update
- Non-renounceable Entitlement Offer
- Imagion Secures Growth Funding
Later from Imagion Biosystems
- Non-renounceable Entitlement Offer Shortfall
- Half-Year Results Release
- Appendix 4D
- 2022 R&D Tax Refund
- Imagion presents ovarian cancer data at AACR conference
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems